ABT
Abbott Laboratories
ABT
Abbott Laboratories
Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for
Agreements will resolve the Gill case and claims involving approximately 2,000 other individuals Abbott and the medical community stand by the safety of preterm infant formulas Regulators and medical
Abbott Laboratories remains a buy, with accelerating earnings growth, margin expansion, and robust segment performance following Q2's double beat and guidance raise. ABT's Exact Sciences acquisition s
Smith & Nephew PLC (LSE:SN) share prices weakened around 3% after the company announced that chief financial officer John Rogers will leave the company at the end of September. The medical technology
Smith & Nephew PLC (LSE:SN) shares fell 3.5% to 1,071.84p early on Wednesday after finance chief John Rogers stepped down from the medical technology company's board with immediate effect. Rogers will
The NACHC and Abbott Food for Health Initiative is a multi-year "food is medicine" effort to support the integration of nutrition as a foundational component of primary care provided by Community Heal
Eli Lilly and Company, Abbott Laboratories, AbbVie, Novo Nordisk A/S, Pfizer, Bristol Myers Squibb, and Gilead Sciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat's st
Schwab U.S. Dividend Equity ETF remains a Buy for its blend of capital appreciation and dividend income. SCHD's top holdings, including ABT, UNH, and MRK, offer underappreciated catalysts and strong d
Ascent Wealth Partners LLC reduced its stake in Abbott Laboratories (NYSE: ABT) by 29.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
ABT's diversified diagnostics/nutrition/medtech segments drive multi-pronged growth prospects, as the management targets a +7% organic growth rate. The recent EXAS acquisition introduces balance sheet
Abbott Laboratories (NYSE:ABT) reported upbeat second-quarter results and raised its full-year adjusted earnings outlook on Thursday.
Abbott Laboratories NYSE: ABT gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is sol
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript